William Blair Issues Optimistic Estimate for DLB Earnings

Dolby Laboratories, Inc. (NYSE:DLB) – William Blair increased their Q4 2025 earnings per share estimates for Dolby Laboratories in a research note issued to investors on Thursday, January 30th. William Blair analyst R. Schackart now anticipates that the electronics maker will post earnings per share of $0.59 for the quarter, up from their prior forecast of $0.53. The consensus estimate for Dolby Laboratories’ current full-year earnings is $2.92 per share. William Blair also issued estimates for Dolby Laboratories’ Q3 2026 earnings at $0.57 EPS.

Several other equities research analysts also recently weighed in on DLB. StockNews.com downgraded Dolby Laboratories from a “strong-buy” rating to a “buy” rating in a report on Friday, January 31st. Rosenblatt Securities reissued a “buy” rating and issued a $100.00 price target on shares of Dolby Laboratories in a report on Thursday, January 30th. Finally, Barrington Research reissued an “outperform” rating and issued a $100.00 price target on shares of Dolby Laboratories in a report on Monday, January 27th.

Dolby Laboratories Stock Performance

Shares of NYSE DLB opened at $84.52 on Monday. The company has a market cap of $8.07 billion, a PE ratio of 31.07 and a beta of 0.98. The business has a 50-day simple moving average of $79.51 and a two-hundred day simple moving average of $75.75. Dolby Laboratories has a fifty-two week low of $66.35 and a fifty-two week high of $89.66.

Dolby Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 19th. Stockholders of record on Tuesday, February 11th will be paid a $0.33 dividend. This represents a $1.32 annualized dividend and a dividend yield of 1.56%. The ex-dividend date of this dividend is Tuesday, February 11th. Dolby Laboratories’s payout ratio is 48.53%.

Insider Transactions at Dolby Laboratories

In related news, CAO Ryan Nicholson sold 10,500 shares of Dolby Laboratories stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $80.18, for a total transaction of $841,890.00. Following the completion of the transaction, the chief accounting officer now directly owns 24,364 shares in the company, valued at approximately $1,953,505.52. This trade represents a 30.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP John D. Couling sold 7,000 shares of Dolby Laboratories stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $80.50, for a total value of $563,500.00. Following the transaction, the senior vice president now owns 106,806 shares of the company’s stock, valued at approximately $8,597,883. This represents a 6.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 175,917 shares of company stock worth $14,272,939 over the last three months. 38.39% of the stock is currently owned by insiders.

Institutional Trading of Dolby Laboratories

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Dolby Laboratories by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,538,583 shares of the electronics maker’s stock worth $117,767,000 after buying an additional 63,293 shares during the last quarter. Lord Abbett & CO. LLC boosted its stake in Dolby Laboratories by 5.8% during the third quarter. Lord Abbett & CO. LLC now owns 284,466 shares of the electronics maker’s stock worth $21,771,000 after buying an additional 15,546 shares during the last quarter. Barclays PLC boosted its stake in Dolby Laboratories by 80.5% during the third quarter. Barclays PLC now owns 33,230 shares of the electronics maker’s stock worth $2,544,000 after buying an additional 14,825 shares during the last quarter. Boston Trust Walden Corp boosted its stake in Dolby Laboratories by 185.3% during the third quarter. Boston Trust Walden Corp now owns 1,075,076 shares of the electronics maker’s stock worth $82,276,000 after buying an additional 698,283 shares during the last quarter. Finally, Edgestream Partners L.P. acquired a new position in Dolby Laboratories during the third quarter worth $3,031,000. 58.56% of the stock is owned by institutional investors and hedge funds.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.